ストックスクリーナーアプリを入手
42.88
4.25%
1.75
アフターアワーズ：
42.88
前日終値:
$41.13
開ける：
$41.68
24時間の取引高:
188.79K
Relative Volume:
0.52
時価総額：
$1.94B
収益：
-
当期純損益:
$-75.27M
株価収益率:
-25.28
EPS:
-1.6963
ネットキャッシュフロー:
$-66.67M
1週間 パフォーマンス:
+13.80%
1か月 パフォーマンス:
+12.52%
6か月 パフォーマンス:
-2.08%
1年 パフォーマンス:
+237.11%
1日の値動き範囲:
$40.53
$43.16
1週間の範囲:
$36.90
$43.41
52週間の値動き範囲:
$12.53
$48.45
Sionna Therapeutics Inc Stock (SION) Company Profile
名前
Sionna Therapeutics Inc
セクター
電話
617-819-2020
住所
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
42.88 | 1.86B | 0 | -75.27M | -66.67M | -1.6963 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Citizens | Mkt Outperform |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-04 | 開始されました | Guggenheim | Buy |
| 2025-03-04 | 開始されました | Stifel | Buy |
| 2025-03-04 | 開始されました | TD Cowen | Buy |
すべてを表示
Sionna Therapeutics Inc (SION) 最新ニュース
Stifel reiterates Buy on Sionna Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Citizens reiterates Sionna Therapeutics stock rating on CF treatment potential By Investing.com - Investing.com Canada
Number of shareholders of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $50 to $63 - Moomoo
Freedom Broker downgrades Sionna Therapeutics (SION) - MSN
SION: Phase II data for two NBD1 stabilizers in CF expected this summer, aiming for superior efficacy - TradingView
Sionna Therapeutics Cut to Hold From Buy by Freedom Broker - Moomoo
Sionna Therapeutics Price Target Maintained With a $38.00/Share by Freedom Broker - Moomoo
Sionna Therapeutics stock rating cut to Hold at Freedom Broker By Investing.com - Investing.com Canada
SION Maintained by Stifel -- Price Target Raised to $55 - GuruFocus
Sionna Therapeutics Price Target Raised to $55.00/Share From $44.00 by Stifel - Moomoo
Wedbush Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Stifel raises Sionna Therapeutics price target on NBD1 data confidence By Investing.com - Investing.com Canada
User - FinancialContent
Wedbush initiates coverage of Sionna Therapeutics (SION) with outperform recommendation - MSN
Sionna Therapeutics, Inc. $SION Shares Purchased by Vanguard Group Inc. - MarketBeat
RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Sionna Therapeutics Develops Next-Generation Cystic Fibrosis Modulators - HarianBasis.co
Wedbush Initiates Coverage of Sionna Therapeutics (SION) - Insider Monkey
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout - TipRanks
LifeSci Capital Maintains Sionna Therapeutics(SION.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Sionna Therapeutics Q1 Net Loss Narrows - Moomoo
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing Earnings - MarketBeat
Guggenheim reiterates Sionna Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Sionna stock ahead of summer data - Investing.com
Wedbush reiterates Sionna Therapeutics stock rating on trial timelines - Investing.com
Sector Update: Healthcare - Moomoo
Wedbush reiterates Sionna Therapeutics stock rating on trial timelines By Investing.com - Investing.com Canada
Sector Update: Healthcare Stocks Advance Premarket Tuesday - Moomoo
Sionna Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sionna Therapeutics Reports Q1 2026 Financial Results and Completes Enrollment in PreciSION CF Phase 2a Trial - Minichart
Sionna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sionna Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Earnings Flash (SION) Sionna Therapeutics Posts Q1 Net Loss $0.60 a Share, vs. FactSet Est of $0.54 Loss - marketscreener.com
Sionna Therapeutics 1Q 2026: Revenue ($27.4M), Net income ($26.78M), EPS ($0.6) — 10-Q Summary - TradingView
Earnings Flash (SION) Sionna Therapeutics Posts Q1 Net Loss $0.60 a Share, Vs. FactSet Est of $0.54 Loss - Moomoo
Sionna Therapeutics Reports First Quarter 2026 Financial Results - The Manila Times
Sionna Therapeutics 1Q Loss/Shr 60c >SION - Moomoo
Two cystic fibrosis trials with summer data expected as Sionna holds $289.9M cash - Stock Titan
Sionna Therapeutics stock hits all-time high at 46.65 USD By Investing.com - Investing.com India
Sionna Therapeutics Insider Sold Shares Worth $13,364,065, According to a Recent SEC Filing - Moomoo
Sionna Therapeutics(SION.US) Director Sells US$13.36 Million in Common Stock - Moomoo
OrbiMed Advisors LLC sells $13.3 million of Sionna Therapeutics (SION) stock - Investing.com UK
Sionna Therapeutics director Peter Thompson sells $13.36m in stock - Investing.com
OrbiMed Advisors LLC sells $13.3 million of Sionna Therapeutics (SION) stock By Investing.com - Investing.com Australia
Sionna Therapeutics director Peter Thompson sells $13.36m in stock By Investing.com - Investing.com Canada
Sionna Therapeutics Inc (SION) 財務データ
収益
当期純利益
現金流量
EPS
Sionna Therapeutics Inc (SION) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
May 08 '26 |
Sale |
44.58 |
59,767 |
2,664,413 |
2,856,461 |
| Thompson Peter A. | Director |
May 07 '26 |
Sale |
44.61 |
48,546 |
2,165,637 |
2,916,228 |
| ORBIMED ADVISORS LLC | Director |
May 11 '26 |
Sale |
46.22 |
184,639 |
8,534,015 |
2,671,822 |
| ORBIMED ADVISORS LLC | Director |
May 08 '26 |
Sale |
44.58 |
59,767 |
2,664,413 |
2,856,461 |
| ORBIMED ADVISORS LLC | Director |
May 07 '26 |
Sale |
44.61 |
48,546 |
2,165,637 |
2,916,228 |
| Thompson Peter A. | Director |
Apr 17 '26 |
Sale |
44.68 |
52,397 |
2,341,098 |
2,967,722 |
| Thompson Peter A. | Director |
Apr 18 '26 |
Sale |
44.52 |
2,948 |
131,245 |
2,964,774 |
| ORBIMED ADVISORS LLC | Director |
Apr 17 '26 |
Sale |
44.68 |
52,397 |
2,341,098 |
2,967,722 |
| ORBIMED ADVISORS LLC | Director |
Apr 18 '26 |
Sale |
44.52 |
2,948 |
131,245 |
2,964,774 |
| Thompson Peter A. | Director |
Apr 15 '26 |
Sale |
44.64 |
235,863 |
10,528,924 |
3,247,025 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):